Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2156 participants
OBSERVATIONAL
2014-02-28
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Acute heart failure syndrome (AHFS) is collectively defined as a gradual or rapid change in heart failure (HF) signs and symptoms resulting in a need for urgent therapy. Heart failure (HF) is one of the most important causes of morbidity and mortality in the industrialized world. The prevalence of symptomatic HF is estimated to range from 0.4 to 2.0% in general European population. The incidence increases rapidly with age, and in Europe. Characteristics, clinical presentation, treatment, and outcomes of HF patients admitted to hospital have been adequately described, in Europe and in the United States. The Euro Heart Failure Survey (EHFS) I with 11 327 patients described the demographics of acutely hospitalized HF patients. The ADHERE registry has data on over 100 000 hospitalizations for AHF from the USA. In-hospital mortality was 4 and 7%, in ADHERE and EHFS I, respectively.
This same sensation of breathlessness is what also drives patients with asthma and chronic obstructive pulmonary disease (COPD) to the ED. Chronic obstructive pulmonary disease (COPD) exacerbation accounts for approximately 1.5 million ED visits in the United States per year. It is the third most common cause of hospitalization, with an estimated 726 000 hospitalizations in 2000 in the USA. Previous studies have demonstrated important differences between guideline recommendations and actual management of COPD exacerbation, either in the ED or during hospitalization.
The diagnosis in front of a dyspneic patient in the ED remains a challenge, because of a low sensitivity of the clinical signs associated with the aging of the population and the variety of underlying diseases. Little is known about the Epidemiology of dyspneic patients in the ED at the European level. Diagnosis, prevalence and treatment of the patients may vary among European countries.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Epidemiologic description of patients presenting to the ED with shortness of breath as main complaint.
* Description of current management in the ED of patients presenting to the ED with shortness of breath as main complaint.
SECONDARY OBJECTIVES
* Sub analysis of ED discharged patients versus admitted patients for characteristics, comparison to recommended care and re-ED visit.
* Determine clinical and/or biological criteria to distinguish between:
* Patients who are treated as outpatients and admitted patients.
* Patients hospitalized in ward and patients admitted to intensive care units (CCU and ICU)
* Prognostic prediction, using clinical and biochemical data
* To determine if ED patients treated for acute heart failure differ from those admitted to hospital.
* Comparison of European data characteristics, investigation, treatment and outcome to similar data in other part of the world.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years or older
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hopital Lariboisière
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Said LARIBI, MD, PhD.
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Said LARIBI, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Lariboisière Hospital, EuSEM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Country: Belgium
Brussels, , Belgium
Country: Finland
Helsinki, , Finland
Country: France
Paris, , France
Country: Germany
Nuremberg, , Germany
Country: Italy
Rome, , Italy
Country: Netherlands
Amsterdam, , Netherlands
Country: Romania
Cluj-Napoca, , Romania
Country: Spain
Santander, , Spain
Country: Turkey
Ankara, , Turkey (Türkiye)
Country: United Kingdom
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HLariboisiere
Identifier Type: -
Identifier Source: org_study_id